Preclinical evaluation of CXCR4 peptides for targeted radionuclide therapy in glioblastoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Preclinical evaluation of CXCR4 peptides for targeted radionuclide therapy in glioblastoma ; volume:9 ; number:1 ; day:15 ; month:7 ; year:2024 ; pages:1-23 ; date:12.2024
EJNMMI radiopharmacy and chemistry ; 9, Heft 1 (15.7.2024), 1-23, 12.2024
- Urheber
-
Waked, Anthony
Crabbé, Melissa
Neirinckx, Virginie
Pérez, Sunay Rodriguez
Wellens, Jasmien
Rogister, Bernard
Benotmane, M. Abderrafi
Vermeulen, Koen
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s41181-024-00282-y
- URN
-
urn:nbn:de:101:1-2410012106195.750046471664
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Waked, Anthony
- Crabbé, Melissa
- Neirinckx, Virginie
- Pérez, Sunay Rodriguez
- Wellens, Jasmien
- Rogister, Bernard
- Benotmane, M. Abderrafi
- Vermeulen, Koen
- SpringerLink (Online service)
Ähnliche Objekte (12)
Struktur-Aktivitätsbeziehung eines CXCR4-mimetischen Peptides
The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma
Radionuclide
Preclinical outcomes of Intratumoral Modulation Therapy for glioblastoma
Disrupting the CXCL12/CXCR4 axis disturbs the characteristics of glioblastoma stem-like cells of rat RG2 glioblastoma
Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy
Convective forces increase CXCR4-dependent glioblastoma cell invasion in GL261 murine model
Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies
Preclinical evaluation of 5-methyltetrahydrofolate-based radioconjugates—new perspectives for folate receptor–targeted radionuclide therapy
Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
Novel therapeutic venues for glioblastoma: novel rising preclinical treatment opportunities
Preclinical and clinical advances to overcome hypoxia in glioblastoma multiforme
Struktur-Aktivitätsbeziehung eines CXCR4-mimetischen Peptides
The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma
Radionuclide
Preclinical outcomes of Intratumoral Modulation Therapy for glioblastoma
Disrupting the CXCL12/CXCR4 axis disturbs the characteristics of glioblastoma stem-like cells of rat RG2 glioblastoma
Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy
Convective forces increase CXCR4-dependent glioblastoma cell invasion in GL261 murine model
Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies
Preclinical evaluation of 5-methyltetrahydrofolate-based radioconjugates—new perspectives for folate receptor–targeted radionuclide therapy
Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
Novel therapeutic venues for glioblastoma: novel rising preclinical treatment opportunities
Preclinical and clinical advances to overcome hypoxia in glioblastoma multiforme
Struktur-Aktivitätsbeziehung eines CXCR4-mimetischen Peptides
The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma
Radionuclide
Preclinical outcomes of Intratumoral Modulation Therapy for glioblastoma
Disrupting the CXCL12/CXCR4 axis disturbs the characteristics of glioblastoma stem-like cells of rat RG2 glioblastoma
Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy
Convective forces increase CXCR4-dependent glioblastoma cell invasion in GL261 murine model
Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies
Preclinical evaluation of 5-methyltetrahydrofolate-based radioconjugates—new perspectives for folate receptor–targeted radionuclide therapy
Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
Novel therapeutic venues for glioblastoma: novel rising preclinical treatment opportunities